Our subsequent experiments revealed that STOML2 triggers the upregulation of PD-L1 expression level and mediates the tumor immune escape indicating that STOML2 contributed to CRC progression via promoting the concurrent of angiogenesis and immunosuppression. Here, CD274 is linked to neoplasm.